Heart scan guides preventive treatment in symptom-free Danish adults
Tests whether CT coronary angiography guides prevention in adults with heart disease risk factors.
Plain-language title generated from the registry record
Registry title: The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Key facts
- Where
- Copenhagen and Herlev, DenmarkSee the 2 sites
Where in Denmark
- Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of CopenhagenCopenhagen, DenmarkNo longer taking part
- The Copenhagen General Population Study, Herlev-Gentofte Hospital, University of Copenhagen, DenmarkHerlev, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Copenhagen University Hospital, Rigshospitalet
- Trial code
- NCT05677386
- Record updated
- 5 November 2026
- Original description
The goal of this randomized controlled clinical trial in asymptomatic individuals with risk factors for cardiovascular disease is to investigate whether a preventive treatment strategy guided by computed tomography coronary angiography (CTCA) provides a patient-centered approach, which ensures optimal protection against serious cardiovascular disease.Read full original descriptionShow less
Prevention of Heart Disease in Adult Danes Using Computed Tomography Coronary Angiography - The DANE-HEART Trial
The goal of this randomized controlled clinical trial in asymptomatic individuals with risk factors for cardiovascular disease is to investigate whether a preventive treatment strategy guided by computed tomography coronary angiography (CTCA) provides a patient-centered approach, which ensures optimal protection against serious cardiovascular disease.
The main question it aims to answer is:
Does preventive treatment guided by CTCA reduce the risk of heart attacks or cardiovascular death as compared to using conventional cardiovascular risk scores.
Participants will be randomized to preventive medical therapy and/or invasive intervention guided by either CTCA (intervention group) or Systematic COronary Risk Evaluation (SCORE) 2 model for cardiovascular risk prediction (control group).
Inclusion: Patients must have at least one of the following cardiovascular risk factors:; >60 years of age; Family history of premature cardiovascular disease (first degree relative with atherosclerotic cardiovascular disease below 60 years); Hypertension (medically treated, or by clinical assessment); Diabetes mellitus; Current or recent (within 12 months) smoker; Known hypercholesterolaemia (total cholesterol >6.0 mmol/L or receiving statin therapy); Rheumatoid arthritis; Systemic lupus erythematosus; Chronic kidney disease stage 3 (estimate glomerular filtration rate 30-59 mL/min/1.73 m2).
Exclusion: Known coronary heart disease or other major atherosclerotic cardiovascular disease; Previous coronary revascularization; Previous myocardial infarction; Heart failure; Stroke / Transient ischemic attack; Peripheral arterial disease; CTCA related factors; Known persistent atrial fibrillation; Known x-ray contrast allergy; Implanted intracardiac metal devices; Known homozygous familial hypercholesterolaemia or other serious inherited disorders of lipid metabolism requiring statin therapy; Statin therapy for >2 years; Prior invasive or non-invasive coronary angiography within the last 5 years; Intolerance of all statins.
Individuals participating in the Copenhagen General Population Study 40 years of age and older, with an estimate glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 will be offered participation in the trial.